TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31479770

Group type: EXPERIMENTAL
Intervention: Acuros dose-to-medium (Dm,m)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Acuros dose-to-water (Dw,m)
Number of subjects: 21

Group type: COMPARATOR
Intervention: AAA
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Acuros Dm,m
Number of subjects: 21
Study: 31051511

Group type: EXPERIMENTAL
Intervention: aMED diet pattern
Number of subjects: 1367

Group type: EXPERIMENTAL
Intervention: AHEI diet pattern
Number of subjects: 1367

Group type: EXPERIMENTAL
Intervention: DASH diet pattern
Number of subjects: 1367

Group type: EXPERIMENTAL
Intervention: HEI diet pattern
Number of subjects: 1367

Group type: EXPERIMENTAL
Intervention: Overall metabolomic analysis
Number of subjects: 1367

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 1367
Study: 27921252

Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg controlled-release tablets
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Oxycodone-Naloxone 10/5 mg controlled-release tablets
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (Oxycodone)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (Oxycodone-Naloxone)
Number of subjects: 180
Study: 26851407

Group type: EXPERIMENTAL
Intervention: Receipt of conditional cash transfers (CCTs)
Number of subjects: 6649

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6649
Study: 24873806

Group type: EXPERIMENTAL
Intervention: Diluted vasopressin injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 22825784

Group type: EXPERIMENTAL
Intervention: Lipocryolysis treatment
Number of subjects: 16
Study: 19683269

Group type: EXPERIMENTAL
Intervention: 8-core biopsy protocol (group 1)
Number of subjects: 269

Group type: COMPARATOR
Intervention: 12-core biopsy protocol (group 2)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Repeat biopsy
Number of subjects: 269
Study: 18154961

Group type: EXPERIMENTAL
Intervention: Heart Failure Sensor (HFS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Swan-Ganz catheter (SG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Echocardiography (ECHO)
Number of subjects: 12
Study: 15536093

Group type: EXPERIMENTAL
Intervention: Syncope unit evaluation
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 103
Study: 11302037

Group type: EXPERIMENTAL
Intervention: Screen-based anesthesia simulator with debriefing
Number of subjects: 31

Group type: COMPARATOR
Intervention: Traditional handout study
Number of subjects: 31
Study: 9403278

Group type: EXPERIMENTAL
Intervention: Felodipine ER, 10 mg once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nifedipine SR, 20 mg twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8427864

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (0.25‐0.5 units/kg per week s.c. given each evening) for 6 months
Number of subjects: 9
Study: 3315286

Group type: EXPERIMENTAL
Intervention: Low-dose metoclopramide and chlorpromazine
Number of subjects: 19

Group type: COMPARATOR
Intervention: High-dose metoclopramide
Number of subjects: 19
Study: 31845733

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise intervention (MG)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Walking intervention (WG)
Number of subjects: 81
Study: 29510711

Group type: EXPERIMENTAL
Intervention: Primaquine anti-relapse treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27347563

Group type: EXPERIMENTAL
Intervention: Rosuvastatin calcium, 20 mg/d
Number of subjects: 17802

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17802
Study: 24486033

Group type: EXPERIMENTAL
Intervention: Minimally invasive lateral sinus elevation (study group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional one-stage lateral sinus elevation (control group)
Number of subjects: 26
Study: 22978103

Group type: EXPERIMENTAL
Intervention: Di'ao Xinxuekang Soft Capsule (DK)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 100
Study: 20305128

Group type: EXPERIMENTAL
Intervention: DASH diet combined with a behavioral weight management program including exercise and caloric restriction
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: DASH diet alone
Number of subjects: 124

Group type: COMPARATOR
Intervention: Usual diet control
Number of subjects: 124
Study: 17560883

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control (placebo or antiarrhythmic agents)
Number of subjects: 303
Study: 15616068

Group type: EXPERIMENTAL
Intervention: Propofol (doses: 0, 0.6, 0.8, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4 mg/kg)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Propofol (doses > or = 1.0 mg/kg)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Propofol (doses not specified)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: SNAP index
Number of subjects: 220
Study: 12161228

Group type: EXPERIMENTAL
Intervention: Group 1a (IDC with recent-onset pulmonary congestion)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Group 1b (IDC without pulmonary congestion)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Group 2 (subjects without heart disease)
Number of subjects: 65
Study: 10357342

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.20%
Number of subjects: 68

Group type: COMPARATOR
Intervention: ropivacaine 0.15%
Number of subjects: 68

Group type: COMPARATOR
Intervention: ropivacaine 0.10%
Number of subjects: 68
Study: 7536681

Group type: EXPERIMENTAL
Intervention: recombinant human granulocyte‐macrophage‐CSF (rhGM‐CSF)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: recombinant human granulocyte‐CSF (rhG‐CSF)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no CSF therapy)
Number of subjects: 32
Study: 2201162

Group type: EXPERIMENTAL
Intervention: Topical terlipressin gel
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 44
Study: 7030227

Group type: EXPERIMENTAL
Intervention: Triple dye
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% neomycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% silver sulphadiazine ointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bismuth subgallate (astringent powder)
Number of subjects: 0
Study: 30852564

Group type: EXPERIMENTAL
Intervention: Long-acting octreotide
Number of subjects: 85
Study: 28183565

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4 (HES) preload
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with phenylephrine infusion
Number of subjects: 30
Study: 25918346

Group type: EXPERIMENTAL
Intervention: CCI 2 (n = 589)
Number of subjects: 1519

Group type: EXPERIMENTAL
Intervention: CCI 3 to 4 (n = 599)
Number of subjects: 1519

Group type: EXPERIMENTAL
Intervention: CCI 5 to 6 (n = 229)
Number of subjects: 1519

Group type: EXPERIMENTAL
Intervention: CCI ≥ 7 (n = 102)
Number of subjects: 1519
Study: 24077886

Group type: EXPERIMENTAL
Intervention: Intraoperative autologous blood re‐transfusion (ABT) filter system combined with a postoperative ABT filter unit
Number of subjects: 118

Group type: COMPARATOR
Intervention: High‐vacuum closed‐suction drainage
Number of subjects: 118
Study: 22472037

Group type: EXPERIMENTAL
Intervention: 42 g pistachios (RSG)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 70 g pistachios (HSG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No pistachios (DCG)
Number of subjects: 90
Study: 19118702

Group type: EXPERIMENTAL
Intervention: Cold steel endonasal endoscopic dacryocystorhinostomy (EES‐DCR) with circular bicanalicular intubation with silicone tubes (CBIST) guided by a soft probe
Number of subjects: 72

Group type: COMPARATOR
Intervention: External dacryocystorhinostomy (E‐DCR)
Number of subjects: 72
Study: 17374698

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 15446669

Group type: EXPERIMENTAL
Intervention: Elderly model
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Family model
Number of subjects: 723
Study: 11391123

Group type: EXPERIMENTAL
Intervention: Remacemide (150 mg twice daily, increasing to 400 mg twice daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Remacemide
Number of subjects: 33
Study: 9721393

Group type: EXPERIMENTAL
Intervention: Chlorous acid preoperative skin antiseptic
Number of subjects: 85

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate scrub solution
Number of subjects: 85
Study: 11271297

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 121

Group type: COMPARATOR
Intervention: Cyclosporin A (CsA) and FK 506
Number of subjects: 121
Study: 3884410

Group type: EXPERIMENTAL
Intervention: Sulodexide (high-dose glycosaminoglycan)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30252869

Group type: EXPERIMENTAL
Intervention: 15% green forage
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 30% green forage
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 45% green forage
Number of subjects: 116
Study: 26829494

Group type: EXPERIMENTAL
Intervention: Algorithmic physiologic management based on blood pressure and arterial waveform analysis
Number of subjects: 94

Group type: COMPARATOR
Intervention: Contemporary standards for blood pressure management
Number of subjects: 94
Study: 25498055

Group type: EXPERIMENTAL
Intervention: Standard triple therapy with CsA, everolimus twice daily and steroids (group A)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Steroid-free immunosuppression (group B)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Triple therapy once daily (group C)
Number of subjects: 139
Study: 22513495

Group type: EXPERIMENTAL
Intervention: 10-session behavioral treatment
Number of subjects: 93

Group type: COMPARATOR
Intervention: three-session brief family intervention
Number of subjects: 93
Study: 20212204

Group type: EXPERIMENTAL
Intervention: Affected eyes
Number of subjects: 454

Group type: COMPARATOR
Intervention: Fellow eyes
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Foveal threshold
Number of subjects: 454
Study: 18511542

Group type: EXPERIMENTAL
Intervention: Minocycline treatment associated with lid hygiene
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lid hygiene only
Number of subjects: 20
Study: 17697902

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI (80/4.5 microg x 2 inhalations)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Budesonide pMDI (80 microg x 2 inhalations)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Formoterol DPI (4.5 microg x 2 inhalations)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 15123221

Group type: EXPERIMENTAL
Intervention: Salbutamol 400 microg via MDI plus spacer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10691818

Group type: EXPERIMENTAL
Intervention: L-arginine (2.4 g/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9432686

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by concurrent chemoradiotherapy and definitive surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Upfront surgery followed by adjuvant radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by definitive concurrent chemoradiation up to 65 Gy radiation dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multimodality program similar to the phase-II protocol with inclusion of definitive surgery
Number of subjects: 0
Study: 1302807

Group type: EXPERIMENTAL
Intervention: Single-dose oral fluconazole (150 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three-day local treatment with miconazole pessaries
Number of subjects: 0
Study: 3895875

Group type: EXPERIMENTAL
Intervention: Lidocaine (300 mg intramuscularly followed by 100 mg intravenously)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study: 31446113

Group type: EXPERIMENTAL
Intervention: Pancrelipase (50,000 units)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 28272011

Group type: EXPERIMENTAL
Intervention: Human reticular acellular dermal matrix (HR-ADM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 12
Study: 27703240

Group type: EXPERIMENTAL
Intervention: BK-SE36 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo/control group
Number of subjects: 0
Study: 24456504

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with temozolomide (Bev-Tem)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with irinotecan (Bev-Iri)
Number of subjects: 63
Study: 22096023

Group type: EXPERIMENTAL
Intervention: Cisplatin plus hypoxic cell cytotoxin, tirapazamine (TPZ)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Cisplatin (control arm)
Number of subjects: 578
Study: 19903333

Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioural program with a vocational approach
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Reference population (disability pensioners with back pain who refused to participate)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Reference population (disability pensioners with other musculoskeletal disorders)
Number of subjects: 89
Study: 17571315

Group type: EXPERIMENTAL
Intervention: Amino acids + glucose + fat emulsion (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Glucose + fat emulsion (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 40
Study: 15478495

Group type: EXPERIMENTAL
Intervention: Amalgam (Dispersalloy)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Spectrum TPH
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SureFil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Esthet‐X
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Esthet‐X + Dyract Flow
Number of subjects: 30
Study: 11547052

Group type: EXPERIMENTAL
Intervention: Routine ureteral stenting after ureteroscopy (group 1)
Number of subjects: 295

Group type: COMPARATOR
Intervention: No ureteral stenting after ureteroscopy (group 2)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Routine ureteral stenting (group 1)
Number of subjects: 295

Group type: COMPARATOR
Intervention: No ureteral stenting (group 2)
Number of subjects: 295
Study: 9493256

Group type: EXPERIMENTAL
Intervention: Compliance data analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated measures of weight loss, drug plasma level, and pill count data
Number of subjects: 0
Study: 7931890

Group type: EXPERIMENTAL
Intervention: High-dose, short-duration ribavirin aerosol therapy (6 gm/100 ml water for 2 hours three times a day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard ribavirin aerosol therapy (6 gm/300 ml water for 18 hours daily)
Number of subjects: 32
Study: 2438880

Group type: EXPERIMENTAL
Intervention: Dithranol (0.1, 0.5, 1, 2%)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dithranol in Lassar's paste
Number of subjects: 30

Group type: COMPARATOR
Intervention: Butantrone (0.66, 1.3, 2.7, 3.9%)
Number of subjects: 30
Study: 29453464

Group type: EXPERIMENTAL
Intervention: Dietitian-led lifestyle modification programme (D-LMP)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional paediatrician-led consultation (P-CON)
Number of subjects: 52
Study: 26183686

Group type: EXPERIMENTAL
Intervention: Piragliatin 200 mg BID
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 24632089

Group type: EXPERIMENTAL
Intervention: Slow theta oscillations (3 Hz)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fast theta oscillations (7 Hz)
Number of subjects: 0
Study: 23739279

Group type: EXPERIMENTAL
Intervention: solution (N-acetylcysteine and simethicone)
Number of subjects: 75

Group type: COMPARATOR
Intervention: water control (100 ml sterile water)
Number of subjects: 75

Group type: COMPARATOR
Intervention: standard control (clear fluids only)
Number of subjects: 75
Study: 20562781

Group type: EXPERIMENTAL
Intervention: Individualized dose regimen of amitriptyline (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Empiric dose regimen of amitriptyline (n=30)
Number of subjects: 60
Study: 18687758

Group type: EXPERIMENTAL
Intervention: Biomarker panel score derived from beta2M, cystatin C, hsCRP, and glucose
Number of subjects: 540

Group type: COMPARATOR
Intervention: Conventional risk factors (age, smoking status, diabetes status)
Number of subjects: 540
Study: 16914413

Group type: EXPERIMENTAL
Intervention: PMEA-coated CPB circuits (n = 19)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-coated CPB circuits (n = 20)
Number of subjects: 39
Study: 11874427

Group type: EXPERIMENTAL
Intervention: Sibutramine (15 mg/day)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 10201469

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg by i.v. infusion immediately before endoscopy)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Placebo (sodium chloride administered in the same fashion)
Number of subjects: 529
Study: 7773086

Group type: EXPERIMENTAL
Intervention: Bisoprolol, 10 mg once a day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Propranolol, 80 mg twice a day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Metoprolol, 100 mg twice a day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2090533

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg once a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 376355

Group type: EXPERIMENTAL
Intervention: Danazol 200 mg daily for 100 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study: 30651007

Group type: EXPERIMENTAL
Intervention: Combined auriculotherapy (LAT + MAT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo auriculotherapy (placebo LAT + placebo MAT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Magneto-auriculotherapy (MAT) alone
Number of subjects: 62
Study: 29945169

Group type: EXPERIMENTAL
Intervention: P27A antigen (10 or 50 μg) with Alhydrogel or GLA-SE (2.5 or 5 μg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: P27A antigen with Alhydrogel
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: P27A antigen with GLA-SE
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control rabies vaccine (Verorab)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: P27A antigen
Number of subjects: 56
Study: 28176150

Group type: EXPERIMENTAL
Intervention: Daily monetary incentives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed monetary incentives
Number of subjects: 0

Group type: COMPARATOR
Intervention: No incentives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily incentive condition
Number of subjects: 0
Study: 25882659

Group type: EXPERIMENTAL
Intervention: Active PEMF therapy (60 minutes; frequency: 12 Hz; intensity: 12 Gauss)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Nonactive PEMF (control group)
Number of subjects: 13
Study: 23727255

Group type: EXPERIMENTAL
Intervention: Multivitamin (MV) supplementation
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 21855759

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of betamethasone acetate 5.7 mg/mL (Group 1)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Dexamethasone 0.1% eyedrops (Group 2)
Number of subjects: 400
Study: 19074930

Group type: EXPERIMENTAL
Intervention: Effective CPAP therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31
Study: 17318417

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHu‐EPO) at doses of 20, 40, 60, 90, 120, and 160 kIU
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHu‐EPO)
Number of subjects: 48
Study: 15260961

Group type: EXPERIMENTAL
Intervention: Oral dextroamphetamine (AMPH, 0.25 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 8
Study: 11699803

Group type: EXPERIMENTAL
Intervention: Intravenous porcine secretin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 9070554

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0
Study: 8436714

Group type: EXPERIMENTAL
Intervention: Back massage with normal conversation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conversation only
Number of subjects: 21

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 21
Study: 3094058

Group type: EXPERIMENTAL
Intervention: Droperidol (15 micrograms/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.65 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30499799

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard gauze dressing
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT) among patients receiving a stoma
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard gauze dressing among patients receiving a stoma
Number of subjects: 300
Study: 28830411

Group type: EXPERIMENTAL
Intervention: Moringa oleifera (M.O.) Lam. leaf powder supplementation (daily for 6 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nutritional counseling (over 6 months)
Number of subjects: 60
Study: 26268774

Group type: EXPERIMENTAL
Intervention: Psychosexual counselling before and after surgery (arm A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: PPI without psychosexual counselling (arm B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Psychosexual counselling (arm A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: PPI alone (arm B)
Number of subjects: 30